India, Sept. 30 -- Immunome, Inc. (IMNM), a clinical-stage targeted oncology company, announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for IM-1340, a potential first-in-class antibody-drug conjugate (ADC) for treating advanced solid tumors.
IM-1340 is designed to target a transport receptor with a unique tumor expression profile across solid tumors, including neuroendocrine tumors, lung cancer, and colorectal cancer.
The drug incorporates HC74, Immunome's proprietary topoisomerase I (TOP1) inhibitor payload. Preclinical studies demonstrated encouraging anti-tumor activity across multiple tumor models, supporting advancement into clinical development.
googletag.cmd.push(...